第61回日本神経学会学術大会

セッション情報

印刷

シンポジウム

[S-33] シンポジウム33
New era of neuroimaging and neurosonology

2020年9月1日(火) 14:15 〜 15:45 第06会場 (岡山コンベンションセンター 2F レセプションホール)

座長：平林 秀裕（独立行政法人国立病院機構 奈良医療センター）,Kim Dong-Eog（Dongguk University, Seoul）

[S-33-1] Dual ASL灌流画像による新たな脳循環動態指標

○中川原 譲二 (医療法人社団新生会大阪なんばクリニック)

Imaging modality of neurological diseases are quickly innovated, that is not only imaging diagnosis but also therapeutic sonology. This symposium is organized to introduce such modern innovative technologies from three internationally sparkling speakers. The first is a very new MRI-based cerebral blood flow measurement (dual ASL), the second the most modernized MRI diagnosis, and the third MR-guided focusing ultrasound (MRgFUS) for essential tremor or even for Parkinson's disease in the future.

[S-33-2] MR Imaging of Neurovascular Abnormality: Experiences from A Quantitative Image-based Stroke Registry

○Dong-Eog Kim (Department of Neurology, Dongguk University Ilsan Hospital)

Imaging modality of neurological diseases are quickly innovated, that is not only imaging diagnosis but also therapeutic sonology. This symposium is organized to introduce such modern innovative technologies from three internationally sparkling speakers. The first is a very new MRI-based cerebral blood flow measurement (dual ASL), the second the most modernized MRI diagnosis, and the third MR-guided focusing ultrasound (MRgFUS) for essential tremor or even for Parkinson's disease in the future.

[S-33-3] 本態性振戦に対する集束超音波療法

○平林 秀裕1, 福留 賢二2, 大西 英之2, 佐藤 直隆2 (1.独立行政法人国立病院機構 奈良医療センター, 2.大西脳神経外科病院)

Imaging modality of neurological diseases are quickly innovated, that is not only imaging diagnosis but also therapeutic sonology. This symposium is organized to introduce such modern innovative technologies from three internationally sparkling speakers. The first is a very new MRI-based cerebral blood flow measurement (dual ASL), the second the most modernized MRI diagnosis, and the third MR-guided focusing ultrasound (MRgFUS) for essential tremor or even for Parkinson's disease in the future.